NCT01263483 - Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Alogliptin and voglibose

Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

DRUG

Alogliptin and voglibose

Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.

DRUG

Voglibose

Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.